文献速递前列腺增生与排尿功能障碍

影响膀胱过度活动症患者经皮胫神经刺激维持治疗复诊的因素

Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder.
PubMed 文献 · BJU Int · 2019-02-03

结果显示,复诊维持治疗者更常报告夜尿显著改善和治疗获益感,夜尿改善与获益感可预测复诊维持治疗;交通、距离和时间投入等因素无差异。

要点

  • 12周PTNS是OAB安全有效的治疗,应答者中夜尿改善和获益感与复诊维持治疗相关
  • 夜尿改善和感知获益可预测复诊维持治疗,而交通、距离等因素无影响
  • 膀胱日记提供更客观的PTNS疗效评估

核心结论

  • 12周PTNS是OAB安全有效的治疗,应答者复诊维持治疗更常报告夜尿显著改善和获益感
  • 夜尿改善和感知获益可预测复诊维持治疗,交通、距离和时间投入等因素无差异

研究设计与样本

  • 患者接受12次每周PTNS治疗,基线和第12周用ICIQ-OAB、ICIQ-LUTSqol和膀胱日记评估

主要发现

  • 三组人口学特征、诊断、基线症状评分和膀胱日记变量无显著差异
  • 组2和组3从基线至第12周总OAB评分显著改善(组2:-1.54±1.85;组3:-1.85±2.28;P<0.05)
  • 复诊维持治疗者夜尿显著改善(膀胱日记差异=-0.4±0.7,P<0.05;ICIQ-LUTSqol差异=-0.48±0.94,P<0.05),且感知获益比例更高(组间差异25.6%;P=0.030)
  • 逻辑回归分析显示夜尿改善和感知获益可预测复诊维持治疗

临床怎么用

  • 对PTNS应答的OAB患者,关注夜尿改善和患者感知获益有助于识别可能复诊维持治疗者
  • 膀胱日记可用于更客观评估PTNS疗效

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify factors influencing return for maintenance percutaneous tibial nerve stimulation (PTNS) treatment after successful completion of a 12-week course of treatment for overactive bladder (OAB). PATIENTS AND METHODS: Patients with OAB symptoms referred for PTNS treatment underwent 12 sessions of weekly PTNS treatment and were evaluated at baseline and week 12 using the International Consultation on Incontinence Questionnaire on OAB, the International Consultation on Incontinence Questionnaire on lower urinary tract symptom-related quality of life (ICIQ-LUTSqol) and a bladder diary (BD). Responders to treatment, evaluated using two patient-reported outcome measures, were invited to return for maintenance treatment when symptoms returned. A PTNS Service Evaluation Questionnaire was used to evaluate factors influencing return for maintenance treatment. RESULTS: Seventy-three patients were evaluated (mean age 58.9 [±14.7] years, 72.6% women) and clustered into three groups: group 1 (n = 25) did not respond to 12 weekly sessions of PTNS treatment; group 2 (n = 17) responded to treatment but did not return for maintenance treatment and group 3 (n = 31) responded to treatment and returned for maintenance treatment. There were no significant differences in demographic characteristics, diagnosis, baseline symptom scores and BD variables among the three groups. Patients belonging to groups 2 and 3 experienced a significant improvement from baseline to week 12 in total OAB scores (group 2: -1.54 ± 1.85; group 3: -1.85 ± 2.28; P < 0.05); however, patients returning for maintenance treatment reported significant improvements specifically in nocturia (BD difference = -0.4 ± 0.7 [P < 0.05] and ICIQ-LUTSqol difference -0.48 ± 0.94 [P < 0.05]), and perceived benefits of the treatment with regard to their OAB symptoms compared to those not returning for maintenance treatment (difference between the two groups 25.6%; P = 0.030). Improvements in nocturia and perceived benefits predicted return for maintenance treatment based on a logistic regression analysis. Factors related to the need for repeat clinic visits, such as transportation, distance and time commitment, were not found to differ between the two groups. CONCLUSIONS: Twelve-session weekly PTNS is a safe and effective treatment for OAB. Responders to treatment returning for maintenance PTNS more often reported significant improvements in nocturia and perceived benefits over time, compared to those not returning for maintenance treatment. The BD provides a more objective assessment of treatment outcome after PTNS treatment.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Salatzki J, Liechti MD, Spanudakis E, et al. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. BJU Int. 2019. PMID: 30552801. doi:10.1111/bju.14651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。